Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price dropped 3.7% during mid-day trading on Friday . The stock traded as low as $7.09 and last traded at $8.07. Approximately 91,393 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 790,984 shares. The stock had previously closed at $8.38.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on MESO shares. Maxim Group upgraded Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 price objective for the company in a report on Tuesday, September 24th. StockNews.com downgraded shares of Mesoblast from a "hold" rating to a "sell" rating in a research report on Wednesday, September 4th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a research note on Thursday, August 29th. Piper Sandler raised Mesoblast from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $4.00 to $11.00 in a report on Tuesday, July 23rd. Finally, Jefferies Financial Group upgraded Mesoblast from a "hold" rating to a "buy" rating in a report on Thursday, August 29th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $11.50.
View Our Latest Report on Mesoblast
Mesoblast Stock Up 1.2 %
The company's 50 day simple moving average is $7.88 and its 200 day simple moving average is $7.29. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.
Institutional Trading of Mesoblast
A number of hedge funds have recently bought and sold shares of the business. Marshall Wace LLP purchased a new stake in shares of Mesoblast during the 2nd quarter valued at $562,000. Chase Investment Counsel Corp purchased a new stake in Mesoblast during the first quarter worth about $298,000. XY Capital Ltd bought a new stake in Mesoblast in the third quarter worth about $244,000. Creative Planning purchased a new position in Mesoblast in the third quarter valued at about $147,000. Finally, XTX Topco Ltd bought a new position in shares of Mesoblast during the 2nd quarter valued at approximately $103,000. 1.43% of the stock is currently owned by institutional investors.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
